Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate Safety and Efficacy of EB-001 Intramuscular (IM) Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Abdominoplasty Surgery

Trial Profile

A Phase 2 Study to Evaluate Safety and Efficacy of EB-001 Intramuscular (IM) Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Abdominoplasty Surgery

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Botulinum toxin E (Primary)
  • Indications Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Acronyms LANTERN-2
  • Sponsors Bonti
  • Most Recent Events

    • 17 Oct 2018 Status changed from recruiting to discontinued.
    • 09 May 2018 According to a Bonti media release, first patient has been dosed, and topline results are expected in the fourth quarter of 2018.
    • 09 May 2018 Status changed from not yet recruiting to recruiting, according to a Bonti media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top